allogene.png
Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021
May 12, 2021 08:30 ET | Allogene Therapeutics, Inc.
Webinar Scheduled for 2:30 PM PT/5:30 PM ET SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company...
allogene.png
Allogene Therapeutics Reports First Quarter 2021 Financial Results 
May 05, 2021 16:02 ET | Allogene Therapeutics, Inc.
CD19 Program Highlights Data from the ALLO-501 ALPHA Study and ALLO-501A ALPHA2 Study to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingLonger Term Follow-Up from...
allogene.png
Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
April 28, 2021 09:24 ET | Allogene Therapeutics, Inc.
Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 StudySeparate Presentation to Include Safety and PK/PD Data on ALLO-647...
allogene.png
Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021
April 27, 2021 08:30 ET | Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
allogene.png
Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma
April 21, 2021 08:30 ET | Allogene Therapeutics, Inc.
RMAT Designation Follows Proof-of-Concept Data from ALLO-715 UNIVERSAL Trial in Heavily Pretreated, Refractory Multiple Myeloma PatientsUNIVERSAL Trial Demonstrated for the First Time that an...
allogene.png
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
April 19, 2021 08:30 ET | Allogene Therapeutics, Inc.
TurboCAR Technology Allows a Programmable Cytokine Signaling to Potentially Control T Cell Exhaustion and Improve Function and Potency of AlloCAR T™ CellsPhase 1 IGNITE Trial Expected to Begin in...
allogene.png
Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
April 12, 2021 08:30 ET | Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn., April 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of...
allogene.png
Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting
April 10, 2021 08:30 ET | Allogene Therapeutics, Inc.
Proprietary TurboCAR Technology Platform Allows Cytokine Activation Signaling to be Selectively Engineered into AlloCAR T™ CellsNew TurboCAR Constructs Can Be Induced by Binding To PDL1/2, Making...
allogene.png
Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
February 25, 2021 16:02 ET | Allogene Therapeutics, Inc.
Presented Initial Phase 1 UNIVERSAL Trial Data on ALLO-715 at The American Society of Hematology (ASH) Meeting Providing First Proof-of-Concept for an AlloCAR T™ Therapy in Relapsed/Refractory...
allogene.png
Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
February 18, 2021 08:30 ET | Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...